Literature DB >> 8988038

Baculovirus P35 inhibits the glucocorticoid-mediated pathway of cell death.

N M Robertson1, J Zangrilli, T Fernandes-Alnemri, P D Friesen, G Litwack, E S Alnemri.   

Abstract

Recent evidence suggests that members of the interleukin-1-beta-converting enzyme (ICE)/Ced-3 family are key mediators of mammalian apoptosis. The known members of the ICE/Ced-3 cysteine protease family are synthesized as proenzymes and require proteolytic processing to produce active, heterodimeric enzymes. The baculovirus protein P35 has recently been shown to inhibit several members of the ICE/Ced-3 cysteine protease family. The importance of ICE/Ced-3 cysteine proteases in programmed cell death prompted us to investigate the role of the apoptotic mediator, CPP32, in the glucocorticoid-mediated cell death pathway. Glucocorticoids induce growth inhibition and apoptosis in sensitive leukemic cell lines, immature thymocytes, and eosinophils. In this report, we demonstrate the enzymatic cleavage of proCPP32 to its active subunits in cells undergoing glucocorticoid-induced apoptotic cell death. Concurrently, in apoptotic cells, PARP, a 116-kilodalton (kDa) human poly(ADP-ribose) polymerase, is proteolytically cleaved to its signature 85-kDa fragment. The proteolytic processing of PARP (the nuclear DNA repair enzyme known to be cleaved in association with apoptosis) is catalyzed by members of the ICE/Ced-3 family. Importantly, stable transfection of the antiapoptotic baculovirus P35 inhibits glucocorticoid-induced apoptotic cell death, proteolytic processing of proCPP32, and cleavage of the 116kDa PARP. We conclude that activation of CPP32 is a critical event in glucocorticoid-induced apoptosis and that this pathway is inhibited at or upstream of CPP32 by baculovirus P35. These data demonstrate that PARP cleavage occurs during glucocorticoid-induced apoptotic cell death and show that this proteolytic process is blocked by the expression of baculovirus P35, supporting a role for activation of the ICE/Ced-3-like cysteine protease during glucocorticoid-induced apoptosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8988038

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  Poly(ADP-ribosylation) and apoptosis.

Authors:  A I Scovassi; G G Poirier
Journal:  Mol Cell Biochem       Date:  1999-09       Impact factor: 3.396

2.  Crystal structure of baculovirus P35: role of a novel reactive site loop in apoptotic caspase inhibition.

Authors:  A J Fisher; W d Cruz; S J Zoog; C L Schneider; P D Friesen
Journal:  EMBO J       Date:  1999-04-15       Impact factor: 11.598

3.  Stable cell lines expressing baculovirus P35: resistance to apoptosis and nutrient stress, and increased glycoprotein secretion.

Authors:  G Lin; G Li; R R Granados; G W Blissard
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001-05       Impact factor: 2.416

4.  The baculovirus antiapoptotic p35 gene also functions via an oxidant-dependent pathway.

Authors:  N K Sah; T K Taneja; N Pathak; R Begum; M Athar; S E Hasnain
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

5.  Functional study on baculovirus anti-apoptosis genes.

Authors:  Yefu Wang; Yipeng Qi; Ying Zhu; Zhida Li; Yiran Yang
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

6.  Commitment and effector phases of the physiological cell death pathway elucidated with respect to Bcl-2 caspase, and cyclin-dependent kinase activities.

Authors:  K J Harvey; J F Blomquist; D S Ucker
Journal:  Mol Cell Biol       Date:  1998-05       Impact factor: 4.272

7.  Cellular stress responses: cell survival and cell death.

Authors:  Simone Fulda; Adrienne M Gorman; Osamu Hori; Afshin Samali
Journal:  Int J Cell Biol       Date:  2010-02-21

8.  Baculoviruses as Vectors for Gene Therapy against Human Prostate Cancer.

Authors:  Lindsay J. Stanbridge; Vincent Dussupt; Norman J. Maitland
Journal:  J Biomed Biotechnol       Date:  2003
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.